1 / 16

Three days vs five days oral cotrimoxazole therapy in non-severe pneumonia

Three days vs five days oral cotrimoxazole therapy in non-severe pneumonia. Kartasasmita C, Samir K. Saha * and Cotrimoxazole Study Group Indonesia and Bangladesh. Back ground. WHO recommendation for Non-Severe pneumonia. Cotrimoxazole or Amoxicillin for 5 days

carol-shannon
Download Presentation

Three days vs five days oral cotrimoxazole therapy in non-severe pneumonia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Three days vs five days oral cotrimoxazole therapy in non-severe pneumonia Kartasasmita C, Samir K. Saha* and Cotrimoxazole Study Group Indonesia and Bangladesh.

  2. Back ground • WHO recommendation for Non-Severe pneumonia. • Cotrimoxazole or Amoxicillin for 5 days • Attention to shorter course of therapy • Better understanding about the role of antibiotic • ICDDR,B experience with drop-outs • Pakistan experience with Short course amoxicillin therapy. • Implications on Compliance, Cost and Microbial resistance.

  3. Aims • To determine the equivalence of 3 and 5 days of oral Cotrimoxazole for the treatment of non severe pneumonia. • To study the impact of cotrimoxazole treatment on carriage strains of Streptococcus pneumoniae and Haemophilus influenzae.

  4. Study design • Double blind, Randomized, Placebo-controlled equivalence trial. • Study was conducted form July 2001 to May 2003. • Ethical clearance was obtained from the ERC of Bangladesh Institute of Child Health and Hasan Sadikin General Hospital.

  5. Inclusion criteria Age 2-59 months WHO defined non-severe pneumonia with or without wheezing. Consent given Exclusion criteria Having severe pneumonia or other very severe disease Allergic to cotrimoxazole Acute Asthma Prior enrollment in the study. Required antibiotic for any other disease(s) Previous hospitalization in last two weeks. Prior antibiotic Weight <4.0 kg Screening of Patients

  6. Enrollment of patients • Baseline assessment • Demographic information • Clinical examination • Randomization • Done in 3 unequal blocks of 4, 6 & 8 in a larger block of 18. • Provided with unique ID • NP swab to isolate Spn and Hi.

  7. Study Medicine • Two bottles for each patients • Blue cap – 1st three days • Contained cotrimoxazole • 1st dose given at health care • White Cap – Last two days • Contained either contrimoxazole (5 days group) or placebo (3 days group).

  8. Follow up • Follow up on day 3, and 5 & 15. • Children were assessed clinically • Compliance to therapy was recorded. • Drug consumption >80% • Not missed >1 dose • Outcome recorded • Resolved – on day 3 & 5 • Failed – day 3 & 5 • Relapsed – day 15 • 2nd NP swab was collected on day 15.

  9. Outcome of treatment • Treatment failure on day 3 (any two of the following) • RR is not reduced by 5 • Temp not reduced by 10C • Mother/caregiver mentioned that baby has deteriorated. • Treatment failure on day 5 • RR is fast • Chest in-drawing • Other danger sign(s) • Relapse: Day 15 • Development of pneumonia again by 15 day. • Clinically resolved • RR age specific cut offs • No danger sign

  10. Analysis • Sample size: 1000 under five non severe pneumonia cases at each site. • Data were double entered and verified in EPI Info 6. • Final analysis was done using EPI Info 6 and SPSS 11.0

  11. Demographic Indicators and Clinical Signs

  12. Number randomized (2022) Day 5 N= 1014 Day 3 N= 1008 Intention to treat analysis Number excluded : -Lost to follow up D5 (LFU) only (63) -Protocol violation (PV) only (44) Combination LFU and PV (22) Number excluded : -Lost to follow up D5 (LFU) only (82) -Protocol violation (PV) only (44) -Combination LFU and PV ( 16) Day 3 Followup Number futher analyzed (872) Number futher analyzed (879) Per Protocol analysis Number failed therapy/died 12/0 Number failed therapy/died 18/0 Number improved (854) Number improved (867) Day 5 Followup Number failed therapy/died 64/1 Number failed therapy/died 68/0 Number resolved (790) Number resolved (799) Day 15 Follow-up Number relapsed (55) Number relapsed (62) Number cured (735) Number cured (737)

  13. Summary Results: Per Protocol Analysis

  14. Impact of treatment: Per protocol

  15. Conclusions • Cotrimoxazole therapy for 3 and 5 days are equivalent. • Treatment with cotrimoxazole increases the nonsusceptibility of NP carriage strains. • Impact of treatment on carriage strains are similar in both the groups. • As a whole, short course cotrimoxazole is effective in a population with high rate of in vitro cotrimoxazole non susceptible Spn and Hi.

  16. COTRIMOXAZOLE STUDY GROUP MEMBERS • INDONESIA • Cissy B. K • Dwi Agustian • Chrysanti • Ni Sayu Dewi • Maula Rifada • Anglita • Vidi Permatagalih • Sri Yusnita • BANGLADESH • Samir K. Saha • Nawshad • M. Hanif • M. Ruhulamin • Billal Hossain • Rafeza Khanam • Tanima Sharmin • Maksuda Islam • Abdullah-Al-Mahin • Masoodul Haque • Shams-el Arifeen CONSULTANTS Eric Simoes, MD. Shamim Qazi, WHO

More Related